by Richard Daverman, PhD
June 3, 2014 -- Jiangsu Hengrui Medicine announced that apatinib, its oral treatment for metastatic gastric cancer, successfully completed a Phase III trial in China. Data from the trial were presented at the recent ASCO conference in Chicago, and the presentation was included as a Best of ASCO selection. Hengrui has filed with the CFDA for marketing approval of apatinib in China. More details....
Stock Symbol: (SHA: 600276)
Help employers find you! Check out all the jobs and post your resume.
